China Pharma Holdings (CPHI) Total Non-Current Liabilities (2010 - 2023)

China Pharma Holdings has reported Total Non-Current Liabilities for 11 years, with the latest figure at $10.5 million in Q1 2023.

• For the quarter ending Q1 2023, Total Non-Current Liabilities changed N/A year-over-year to $10.5 million; the trailing twelve-month figure through Mar 2023 stood at $10.5 million (changed N/A YoY), and the FY2022 full-year result was $11.1 million, down 24.71% from the prior year.
• Total Non-Current Liabilities for Q1 2023 stood at $10.5 million, down from $11.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $14.7 million in Q4 2021, with the low at $9.6 million in Q3 2021.
• Historically, Total Non-Current Liabilities has averaged $11.0 million across 5 years, with a median of $10.5 million in 2023.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 42.28% — and 2022, when it slipped 24.71%.
• China Pharma Holdings' Total Non-Current Liabilities stood at $10.6 million in 2019, then slipped by 2.18% to $10.4 million in 2020, then jumped by 42.28% to $14.7 million in 2021, then fell by 24.71% to $11.1 million in 2022, then declined by 5.3% to $10.5 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $10.5 million (Q1 2023), $11.1 million (Q4 2022), and $14.7 million (Q4 2021), per Business Quant data.